Company: HCWB
Filing Date: 2025-04-14
Form Type: 8-K
Source: 0000950170-25-053745
Chunk: 1

Company: HCW Biologics Inc.
Filing Date: 2025-04-14
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

On April 4, 2025, the Company submitted a preliminary Registration Statement to the SEC covering the resale of the Commitment Shares, which represents the payment of the Investor’s Commitment Fee, and shares of the Company’s common stock which may be issued from time to time under the Equity Purchase Agreement for public resale. On April 8, 2025, the Company received a letter from the staff of the SEC that provided that the SEC had not reviewed and will not review the Registration Statement. The Company will be requesting that the SEC accelerate the effectiveness of the Registration Statement to a date on or about April 16, 2025. Promptly thereafter, the Company will file its final prospectus under Rule 424(b)(3) with the SEC.

This Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The opinion of Clark Hill PLC relating to the validity of the issuance and sale of the shares of the Company’s common stock pursuant to the Equity Purchase Agreement and the Registration Rights Agreement is attached hereto as Exhibit 5.1.